Yong Hak Choi

US Patent:

7446127, Nov 4, 2008

Filed:

Aug 26, 2004

Appl. No.:

10/926615

Inventors:

Yong Moon Choi - Pine Brook NJ, US
Hunwoo Shin - Livingston NJ, US
Palanichamy Ilankumaran - Pinerbrook NJ, US
Hong Wook Kim - Lincoln Park NJ, US

Assignee:

SK Holdings Co, Ltd. - Seoul

International Classification:

A01N 43/16
C07D 263/30

US Classification:

514458, 548235

Abstract:

There are disclosed derivatives of 3-chromancarboxylic acid represented by formula I.

US Patent:

7456293, Nov 25, 2008

Filed:

Mar 28, 2006

Appl. No.:

11/391031

Inventors:

Yong Moon Choi - Pinebrook NJ, US
Hunwoo Shin - Livingston NJ, US
Palanichamy Ilankumaran - Pinebrook NJ, US

Assignee:

SK Holding Co., Ltd - Seoul

International Classification:

A61K 31/4184
C07D 235/04

US Classification:

5483101, 514394

Abstract:

The present invention is concerned with racemic or enantiomerically enriched substituted carboxylic acids and derivatives thereof represented by Formula 1;.

US Patent:

7598279, Oct 6, 2009

Filed:

Apr 20, 2006

Appl. No.:

11/407526

Inventors:

Yong Moon Choi - Pinebrook NJ, US
Choon-Gil Kim - Daejon, KR
Han-Ju Yi - Daejeon, KR
Young-Sun Kang - Daejeon, KR
Hyun-Seok Lee - Daejeon, KR

Assignee:

SK Holdings Co., Ltd. - Seoul

International Classification:

A61K 31/445
C07D 401/12
C07D 249/08
C07D 249/04

US Classification:

514359, 514281, 514283, 548250, 548255, 5482622

Abstract:

Azole compounds containing carbamoyl group and pharmaceutically useful salts thereof are described. The compounds are effective anticonvulsants which are used in the treatment of disorders of the central nervous system, especially as anxiety, depression, convulsion, epilepsy, migraine, bipolar disorder, drug abuse, smoking, ADHD, obesity, sleep disorder, neuropathic pain, stroke, cognitive impairment, neurodegeneration, stroke and muscle spasm.

US Patent:

20050002987, Jan 6, 2005

Filed:

Jun 16, 2004

Appl. No.:

10/869195

Inventors:

Yong Moon Choi - Pine Brook NJ, US
Kwon Kim - Palisades Park NJ, US

International Classification:

A61K009/70
A61K009/14

US Classification:

424434000, 424489000

Abstract:

Diazepam is administered intranasally in the form of specific microemulsions having advantageous properties. The microemulsions are comprised of about equal quantities of a fatty acid and water with the remainder being a hydrophilic surfactant, a polar solvent and an alcohol in a weight ratio such that alcohol is present in a greater quantity by weight than either of the other two. Nasal administration of the subject microemulsions produces a high plasma concentration of diazepam nearly as fast as intravenous administration. The present microemulsions are particularly suitable for a prompt and timely treatment of patients in the acute and/or emergency treatment of status epilepticus and other fever-induced seizures.

US Patent:

20060058548, Mar 16, 2006

Filed:

Nov 3, 2005

Appl. No.:

11/266555

Inventors:

Yong Choi - Pine Brook NJ, US
Min Kim - Montville NJ, US

International Classification:

C07D 217/12

US Classification:

560157000, 546146000

Abstract:

A process for preparing O-carbamoyl aminoalcohols represented by Formula I wherein: n is an integer from 0 and 5;

US Patent:

20060194873, Aug 31, 2006

Filed:

Sep 15, 2005

Appl. No.:

11/227247

Inventors:

Yong Choi - Pine Brook NJ, US
Robert Gordon - Robbinsville NJ, US
Gerald Novak - Skillman NJ, US
Carlos Plata-Salaman - Zionsville IN, US
Roy Twyman - Doylestown PA, US
H. White - Salt Lake City UT, US
Boyu Zhao - Lansdale PA, US

International Classification:

A61K 31/325

US Classification:

514483000, 514489000

Abstract:

This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R, R, R, R, Rand Rare independently selected from the group consisting of hydrogen and C-Calkyl; wherein C-Calkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C-Calkyl, C-Calkoxy, amino, nitro and cyano).

US Patent:

20080317883, Dec 25, 2008

Filed:

Oct 22, 2007

Appl. No.:

11/876194

Inventors:

Yong Moon Choi - Pine Brook NJ, US
Robert Gordon - Robbinsville NJ, US
Magali Haas - Corinth NY, US
Ewa Malatynska - Doyletown PA, US

International Classification:

A61K 36/38
A61K 31/27
A61K 31/5375
A61K 31/55
A61K 31/335
A61K 31/553
A61K 38/06
A61P 25/24
A61K 38/02
A61K 31/445
A61K 31/343
A61K 31/496
A61K 31/381
A61K 36/67

US Classification:

424730, 514489, 514483, 5142378, 514217, 514450, 51421113, 514321, 514469, 51425406, 514438, 51425405, 5142388, 51421402, 424734, 514 18, 514 2

Abstract:

The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more carbamate compounds of Formula 1 and/or Formula 2 as herein defined and shown below for the treatment of depression.The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one additional antidepressant.

US Patent:

20110152362, Jun 23, 2011

Filed:

Nov 15, 2007

Appl. No.:

11/940710

Inventors:

Yong Moon CHOI - Pine Brook NJ, US
Robert Gordon - Robbinsville NJ, US
Gerald P. Novak - Skillman NJ, US
Carlos R. Plata-Salaman - Zionsville IN, US
Roy E. Twyman - Doylestown PA, US
H. Steve White - Salt Lake City UT, US
Boyu Zhao - Lansdale PA, US

International Classification:

A61K 31/27
A61P 25/08

US Classification:

514479, 514478, 514483

Abstract:

This invention is directed to methods for preventing, treating, reversing, inhibiting or arresting epilepsy and epileptogenesis in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II), or a pharmaceutically acceptable salt or ester thereof:wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R, R, R, R, Rand Rare independently selected from the group consisting of hydrogen and C-Calkyl; wherein C-Calkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C-Calkyl, C-Calkoxy, amino, nitro and cyano).